Kyntra Bio, Inc. - Asset Resilience Ratio
Kyntra Bio, Inc. (KYNB) has an Asset Resilience Ratio of 40.24% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read KYNB current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Kyntra Bio, Inc.'s Asset Resilience Ratio has changed over time. See KYNB free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Kyntra Bio, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Kyntra Bio, Inc. asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $40.67 Million | 40.24% |
| Total Liquid Assets | $40.67 Million | 40.24% |
Asset Resilience Insights
- Very High Liquidity: Kyntra Bio, Inc. maintains exceptional liquid asset reserves at 40.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kyntra Bio, Inc. Industry Peers by Asset Resilience Ratio
Compare Kyntra Bio, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Seegene Inc
KQ:096530 |
Biotechnology | 24.96% |
Annual Asset Resilience Ratio for Kyntra Bio, Inc. (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Kyntra Bio, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.37% | $41.11 Million | $119.59 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $214.53 Million | -- |
| 2023-12-31 | 28.78% | $121.90 Million | $423.53 Million | -14.87pp |
| 2022-12-31 | 43.65% | $266.31 Million | $610.09 Million | +13.42pp |
| 2021-12-31 | 30.24% | $233.97 Million | $773.82 Million | +29.25pp |
| 2020-12-31 | 0.98% | $8.14 Million | $826.84 Million | -46.54pp |
| 2019-12-31 | 47.53% | $407.49 Million | $857.40 Million | -12.90pp |
| 2018-12-31 | 60.43% | $532.14 Million | $880.60 Million | +53.52pp |
| 2017-12-31 | 6.91% | $62.06 Million | $898.65 Million | -10.00pp |
| 2016-12-31 | 16.91% | $79.40 Million | $469.55 Million | +10.99pp |
| 2015-12-31 | 5.92% | $27.85 Million | $470.57 Million | +2.95pp |
| 2014-12-31 | 2.97% | $14.36 Million | $483.53 Million | -12.68pp |
| 2013-12-31 | 15.65% | $46.48 Million | $296.95 Million | +15.27pp |
| 2012-12-31 | 0.38% | $1.02 Million | $265.59 Million | -- |
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible fact… Read more